Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer

Key Inclusion Criteria:

- Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC
histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.

- Patient meets the FDA-approved indication for Atezolizumab treatment in NSCLC.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

- Ability to provide informed consent.

- Adequate hematological, liver and kidney function.

- Must be willing to implement contraception throughout study and for the 8 weeks
following last study drug administration.

Key Exclusion Criteria:

- Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration.
Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to
registration

- Other concurrent investigational therapy (utilized for a non-FDA-approved indication
and in the context of a research investigation).

- Pregnant women.

- Nursing women.

- Men or women of childbearing potential who are unwilling to employ adequate
contraception during treatment and 8 weeks following the completion of study drug
treatment.

- Allergy to measles vaccine or history of severe reaction to prior measles vaccination.

- History of organ transplantation.